Edit
Accro Bioscience(Suzhou)Limited
https://www.accropeutics.com/Last activity: 14.09.2026
Probably Closed
Accro Bioscience(Suzhou)Limited
Location: China
Total raised: $62M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.05.2026 | Series C | $50M | Lilly Asia... |
| 16.03.2025 | Series B | $12M | - |
Mentions in press and media 12
| Date | Title | Description |
| 14.09.2026 | Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development | NEW YORK and SUZHOU, China, Sept. 14, 2026 /PRNewswire/ -- On September 14, 2026 (China Standard Time, UTC+8), Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement ... |
| 13.08.2026 | Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona | NEW YORK and SUZHOU, China, Aug. 13, 2026 /PRNewswire/ -- Accro Bioscience, a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, today announced that it will present efficacy ... |
| 19.05.2026 | Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases | Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis NEW YORK and SUZH... |
| 04.09.2025 | Accro Bioscience to Present Phase II Data of AC-201 for Plaque Psoriasis at the European Academy of Dermatology & Venereology Congress 2025 in Paris | NEW YORK and SUZHOU, China, Sept. 4, 2025 /PRNewswire/ -- Accro Bioscience (Accropeutics), a clinical-stage biotech company focused on molecular mechanisms of regulated cell death and related pathogenesis in human diseases, today announced ... |
| 21.05.2025 | Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis | Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing groups at Week 12 AC-201 was generally well tolerated at all dose levels with no SAEs or AEs leading to discontinuation Efficacy and safety findi... |
| 16.03.2025 | Accropeutics: $12 Million (Series B+) Closed For Developing Therapeutics For Immune Mediated Diseases | Accropeutics, a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune-mediated diseases, announced the closing of its $12 million Series B P... |
| 15.03.2025 | Accropeutics Secures $12 Million to Propel Innovative Therapies | In the bustling world of biotechnology, Accropeutics Inc. has just made waves. The company, based in Suzhou, China, has successfully secured $12 million in Series B Plus financing. This funding round was led by Shenzhen Capital Group (SCGC)... |
| 14.03.2025 | nunu.ai Raises $6m in Seed Funding | nunu.ai, a San Francisco, CA-based startup building AI agents capable of testing and playing games, raised $6m in Seed funding. The round was co-led by Tirta Ventures and a16z speedrun. The company intends to use the funds to expand operati... |
| 14.03.2025 | Accropeutics Secured $12 Million in Series B Plus Financing | Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST)... |
| 14.03.2025 | Accropeutics Raises $12M in Series B Plus Financing | Accropeutics, a Suzhou, China-based clinical-stage biotechnology company that develops novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, raised $12M in Series B funding. The round was ... |
Show more